FDA rejects Vivus fat-fighting pill Qnexa
Hopes sank that the first new prescription weight-loss pill in more than a decade would be approved for sale when a key federal advisory panel rejected the drug on Thursday amid lingering safety concerns.
U.S. advisers reject Vivus fat-fighting pill
U.S. health advisers narrowly rejected Vivus Inc's experimental weight-loss pill, saying there was not enough data to merit approval.
KKR shares slip 3 percent in long-awaited debut
The long-anticipated U.S. stock debut of Kohlberg Kravis Roberts & Co proved a disappointment on Thursday as investors shied away from the private equity firm that made its name with the leveraged buyout of RJR Nabisco in 1988.
Discovery says infringement case v Amazon not new
A patent infringement lawsuit filed on Wednesday against Amazon.com was a procedural move and not a new lawsuit, according to Discovery Communications Inc, which filed the complaint.
U.S. judge dismisses suit filed by GE shareholders
A U.S. judge dismissed a lawsuit against General Electric Co on Thursday that accused the largest U.S. conglomerate of failing to warn investors of the 2008 profit drop that marked the beginning of a two-year downturn for the company.
Wall Street reform clears Congress
The Congress on Thursday approved the broadest overhaul of financial rules since the Great Depression and sent it to President Barack Obama to sign into law.
Google profit misses Wall Street view
Google Inc missed Wall Street's profit estimates in its second quarter after a spike in expenses offset a 24 percent revenue jump, a rare stumble for a company accustomed to shattering financial expectations.
Goldman will pay $550 million to settle SEC charges
Goldman Sachs Group Inc agreed to pay $550 million to regulators to settle civil fraud charges over how it marketed a subprime mortgage product, ending a weeks long probe that rattled clients and weighed on its share price.
Wall Street recoups losses on BP and Goldman
Stocks ended little changed on Thursday, recouping losses late in the day, led by a sudden turnaround in Goldman Sachs and BP.
Goldman to pay record $550 million to settle SEC charges
Goldman Sachs has agreed to pay a record $550 million to settle fraud charges brought by the Securities and Exchange Commission, the financial regulator said on Thursday. In its charges against Goldman, the SEC said the investment bank had misled investors in a subprime mortgage product.
Jobless claims fall, manufacturing stumbles
New U.S. claims for jobless benefits tumbled to a near two-year low last week, but a modest gain in industrial output and a third monthly drop in wholesale prices in June confirmed a slackening in the economy's recovery.
Carlyle strikes $3.8 billion deal for NBTY
Carlyle Group struck a $3.8 billion deal on Thursday to buy U.S. nutritional supplements maker NBTY Inc , beating several other buyout firms to clinch one of the biggest private equity deals so far this year.
iPhone recall seen unlikely at Apple event
Apple Inc is likely to announce a fix for the iPhone 4's reception problems, rather than a recall, at a surprise press conference on the device on Friday, analysts said.
Goldman shares rise on SEC announcement
Securities regulators on Thursday said they will make a major enforcement announcement, fueling talk that a deal has been reached in their lawsuit against Goldman Sachs Group Inc .
FCC eyes satellite spectrum for broadband use
U.S. regulators proposed easing restrictions on satellite companies in a move aimed at freeing more airwaves to feed the growing demand for wireless broadband services.
CORRECTED: SEC to announce major enforcement action
Securities regulators on Thursday said they will make a major enforcement announcement, fueling talk that a deal has been reached in their lawsuit against Goldman Sachs Group Inc .
Vivus says weight loss with pill unprecedented
Vivus Inc, hoping to win approval to sell the first new prescription diet drug in more than a decade, told U.S. medical advisers on Thursday its weight-loss pill gives patients a safe option for shedding pounds and improving their health.
FDA panel rejects Vivus weight-loss drug Qnexa
U.S. health advisers narrowly rejected Vivus Inc's experimental weight-loss pill, saying there was not enough data to merit approval.
Apple to address iPhone 4 flaw but recall unlikely
Apple Inc is likely to announce a fix for the iPhone 4's reception problems on Friday, hoping to stem a growing chorus of complaints and avert any lasting damage to its carefully earned reputation for quality products.
KKR makes subdued NYSE debut, shares slip
Storied buyout firm Kohlberg Kravis Roberts & Co made its long-awaited debut on the New York Stock Exchange on Thursday, but the start was subdued and shares traded slightly below their opening price.
Still plenty of demand for iPad: survey
Apple Inc has already sold more than three million of its iPad tablet computers in just over three months, but there is still more demand out there, a new survey showed on Thursday.
JPMorgan beats Street
JPMorgan Chase & Co posted better-than-expected quarterly earnings on Thursday as it wrote off fewer bad loans in the second quarter, but executives warned they were uncertain about the economic outlook for the rest of the year.
JPMorgan took more risk in Q2 commodities
JPMorgan Chase & Co raised its commodity trading risk in the second quarter, the first time in nine months, but earned less from the sector as prices fell and the bank lost out on a large coal bet.
Vivus' weight-loss drug faces key U.S. test
The first potential U.S. prescription weight-loss pill in more than a decade could move closer to market on Thursday if it can overcome safety hurdles that have plagued diet drugs for years and led to tepid sales despite the growing number of obese Americans.
CORRECTED: Vivus' weight-loss drug faces key U.S. test
(Corrects share price in last paragraph from $2.11 to $12.11)
Wall Street falls on weak data
Stocks weakened on Thursday as more signals the pace of the economic recovery is slowing worried investors.
Wall Street reform passes, goes to Obama for signing
The U.S. Congress on Thursday approved the broadest overhaul of financial rules since the Great Depression and sent it to President Barack Obama to sign into law.
Boeing Dreamliner delivery may slip
Boeing Co said on Thursday that issues raised in its 787 Dreamliner flight tests could delay first delivery of the long-awaited carbon-composite aircraft into the first part of 2011, but the company also expects an uptick in new plane demand over the next two decades.
Senate approves sweeping Wall St reform bill
The Senate on Thursday by a vote of 60 to 39 approved the most sweeping overhaul of bank and capital market regulation in decades, sending it on to President Barack Obama to be signed into law.
Rivalries, economy cloud Google expectations
Investors have muted expectations for Google Inc's second-quarter results, as economic clouds and shifts in the company's strategy dampened hopes that it will beat Wall Street estimates.